K2 Medical Research

What K2 Medical Research does

K2 Medical Research is a privately-held clinical research site network operating Phase I-IV trials across neurodegenerative (Alzheimer's, Parkinson's), psychiatric (depression, anxiety, PTSD, addiction), cardiometabolic, hepatic (NASH/NAFLD), rheumatologic, GI, biomarker, diagnostic, and vaccine indications. The company runs 10 sites across Florida (Orlando/Maitland HQ, Tampa, Daytona Beach, Winter Garden, The Villages), Tennessee (Nashville), Rhode Island (East Providence), and Massachusetts (Foxboro/K2 Boston), with the newest facility being a 7,000 SF flagship featuring on-site laboratory, pharmacy, and infusion suite. Co-founders Sean Stanton (CEO; 28 years of industry experience, having stood up 26 prior trial sites and contributed to 50+ drug approvals) and Brandon Lenox, DO (CMO), lead an executive bench that includes a CFO, CAO, SVP of Marketing/Patient Engagement, VP of Compliance, and directors across pharmacy, laboratory, regulatory, psychometric operations, and digital marketing.

The company provides site-based clinical trial execution services to pharmaceutical sponsors, biotech firms, and CROs, generating revenue through per-study professional services contracts covering patient enrollment, trial conduct, and data collection. Reported operational metrics include 95% diary compliance, 4-day Reg Doc/IRB submission times, 5-day contract turnarounds, 14-day award-to-First-Patient-In timelines, and zero FDA 483s in company history. The site mix spans memory-loss specialty (The Villages), Phase I capability (K2 Phase One), and multi-therapeutic general sites, with each location led by local principal investigators across psychiatry, neurology, cardiology, endocrinology, and internal medicine.

K2 monetizes through sponsor study contracts while simultaneously building a patient-recruitment funnel via the K2TrekTogether referral program ($100 per qualified referral), community health fairs, physician partnerships with primary care and assisted-living providers, and direct-to-patient digital marketing across web, social, and email. The business is backed by TPG (private equity investment, June 2024) and is executing an active expansion strategy that includes the K2 Metro Research joint venture with MetroHealth to integrate trials into routine healthcare delivery, and an AI-driven pre-screening pilot with RetiSpec to accelerate Alzheimer's candidate identification.

Name

K2 Medical Research

Legal name

K2 Medical Research

Website

https://k2med.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

K2 Medical Research is a privately-held, TPG-backed clinical research site network operating 10 Phase I-IV trial facilities across Florida, Massachusetts, Rhode Island, and Tennessee, serving pharmaceutical and biotech sponsors in Alzheimer's, psychiatry, cardiometabolic, and hepatic indications.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG), Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts) (HLAGACAC)

Keywords

• Clinical trial services
• Clinical research site network
• Phase I-IV trials
• Alzheimer's research
• Patient recruitment services

Headquarters

HQ city

Orlando

HQ country

United States

HQ region

North America

Offices10 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Clinical Trial Services: K2 Medical Research operates clinical research sites conducting Phase I-IV trials for pharmaceutical sponsors, biotech companies, and CROs. Revenue is generated through study contracts for patient enrollment, trial conduct, and data collection services.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

K2 Medical Research operates a multi-site clinical research network conducting Phase I-IV clinical trials across therapeutic areas including neurodegenerative diseases (Alzheimer's, Parkinson's), cardiometabolic conditions, psychiatric disorders, liver disease, vaccines, and general medicine. The company sells clinical trial execution services to pharmaceutical sponsors, biotech firms, and CROs, while recruiting patients through physician referrals, community outreach, and a referral program.

Product overview

K2 Medical Research operates as a network of clinical research sites conducting multiphasic Phase I-IV clinical trials. The core offering consists of geographically distributed clinical research facilities across Florida (Orlando/HQ, Maitland, Tampa, Winter Garden, Daytona Beach, The Villages), Tennessee (Nashville), Rhode Island (East Providence), and Massachusetts (Boston), plus the K2 Metro Research partnership venture with MetroHealth. The company focuses on neurodegenerative diseases (particularly Alzheimer's), cardiometabolic conditions, psychiatric disorders, liver disease, vaccines, and general medicine. Services include the K2TrekTogether referral program. Each site is led by local Principal Investigators and shares the mission of advancing medicine while making clinical research accessible at the local community level.

Differentiator

Problem solved

Functional benefit

Products and services

• K2 Medical Research Clinical Trial Site Network A network of clinical research sites conducting Phase I-IV clinical trials for pharmaceutical sponsors, biotech companies, and CROs across therapeutic areas including Alzheimer's, Parkinson's, mental health, cardiovascular, metabolic, liver, vaccine, rheumatology, and general medicine.
• K2 Boston 7,000 SF clinical research facility in Foxboro, MA with on-site laboratory, pharmacy, and infusion suite conducting trials in neurology, psychiatry, cardiometabolic health, endocrinology, and general medicine.
• K2 Orlando (Headquarters) Headquarters location in Orlando, FL serving as the main administrative center of the K2 network and conducting trials across multiple therapeutic areas.
• K2 Maitland Clinical research facility in Maitland, FL (541 S Orlando Avenue, Suite 100) conducting trials in psychiatry, cardiovascular disease, and general medicine.
• K2 Tampa Clinical research facility in Tampa, FL (5130 Sunforest Drive, Suite 110) focused on psychiatric and neurological clinical trials.
• K2 Nashville Clinical research facility in Nashville, TN (509 Craighead Street, Suite 110) conducting trials in sleep neurology and related therapeutic areas.
• K2 The Villages Clinical research facility serving The Villages, FL area (1400 US HWY 441 North, Suite 537 and 8577 NE 138th Lane, Lady Lake) specializing in Alzheimer's disease, chronic liver disease, obesity, and vaccine research.
• K2 Winter Garden Clinical research facility in the greater Central Florida area (17309 Pagonia Road, Clermont, FL 34711) conducting trials in neurodegenerative diseases, metabolic conditions, and vaccines.
• K2 Daytona Beach Clinical research facility in Daytona Beach, FL (2595 W. International Speedway Blvd) serving the local community with clinical trial opportunities.
• K2 East Providence Clinical research facility in East Providence, RI focused on neurology and psychiatry clinical trials.
• K2TrekTogether Referral Program Patient referral program offering $100 per qualified referral for family and friends who refer each other for clinical research trials, with no limit on referrals.

Quantifiable outcome

• 5,000+ clinical trials conducted
• +4 more outcomes

Named customers2 records

Segments6 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Partnerships

Four partnerships are on record, tiered minor and core.

• CaringKindminorStrategic or Co-development Partner · 2 June 2026Sean Stanton, CEO of K2 Medical Research, serves on CaringKind's Board of Directors. CaringKind is the leading expert on Alzheimer's and dementia care since 1978.
• NKGen BiotechcoreStrategic or Co-development Partner · 19 May 2026K2 Medical Research is one of three additional clinical trial sites activated for NKGen Biotech's Phase 2 study of troculeucel in moderate Alzheimer's disease. The expansion extends NKGen's U.S. clinical footprint to include Northeast and Southeast regions, with K2 actively enrolling patients.
• MetroHealth Inc.coreStrategic or Co-development PartnerK2 Medical Research and MetroHealth Inc. announced a partnership in a groundbreaking venture called K2 Metro Research, integrating clinical research as a fundamental component of everyday healthcare practice in Holly Hill, FL.
• Magruder Eye InstituteminorStrategic or Co-development PartnerK2 Medical Research teamed up with Magruder Eye Institute and RetiSpec in a research pilot to study how RetiSpec's AI-driven eye test can reduce time required to identify and recruit eligible candidates for Alzheimer's clinical trials.

Scale indicators10 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Velocity Clinical Research: Multi-site SMO network conducting Phase II–IV trials across therapeutic areas including CNS and cardiometabolic, with comparable geographic breadth and sponsor-focused service model. Directly competes with K2 for site-selection decisions by pharma/biotech sponsors.
• Flourish Research: Privately held multi-site clinical research organization operating across the U.S. with therapeutic focus areas overlapping K2's neurology, psychiatry, and cardiometabolic portfolio.
• Javara: Integrated Research Organization that partners with healthcare systems to embed clinical trials as a care option — directly comparable to K2's K2 Metro Research partnership with MetroHealth and the 'Clinical Research as a Care Option' positioning.
• Circuit Clinical: Multi-site SMO with an integrated research organization model, competing in the same therapeutic mix (CNS, cardiometabolic, vaccines) and targeting similar sponsor and patient recruitment strategies.

Broad incumbents

• Medpace: Mid-to-large global CRO with embedded site relationships, operating across all therapeutic areas including CNS. Competes with K2 indirectly for sponsor trial allocation where K2 sites could be embedded in Medpace-managed studies.
• ICON plc: Global CRO with site-management capabilities (formerly PRA Health). K2 competes for the Phase II–IV site work that ICON increasingly pulls in-house or onto preferred-site networks.
• IQVIA: Largest CRO with vertically integrated site network (IQVIA Research & Development Solutions). Anchors many large pharma relationships that K2 must compete against for site-of-record and patient enrollment work.
• Labcorp Drug Development: Now Fortrea, a global CRO spun out of Labcorp with central lab and site coordination capabilities. Competes with K2 across CNS, cardiometabolic, and vaccine trials where central lab + site bundle is preferred.

Others

• Alzheimer's Drug Discovery Foundation (ADDF) Clinical Trials: Not a direct peer but a funder/aggregator of Alzheimer's clinical trials. K2's CNS-heavy portfolio overlaps the trial pipeline ADDF supports, and ADDF referrals could feed K2 site enrollment.
• CureSearch: Clinical trial acceleration platform supporting pediatric and adult oncology trials. Tangentially related ecosystem player; included as a representative trial-funnel and patient-engagement comparator rather than direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/k2_medresearch
• Facebookfacebook.com/K2MedicalResearch
• LinkedInlinkedin.com/company/k2medicalresearch
• Instagraminstagram.com/k2medicalresearch

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about K2 Medical Research